Skip to main content

You must have JavaScript enabled in order to access this part of the site. Please enable JavaScript and then reload this page in order to continue.

Prior Authorization Criteria for Burosumab-Twza (Crysvita) to be Updated for Texas Medicaid Effective November 1, 2020

Last updated on

Note: Texas Medicaid managed care organizations (MCOs) must provide all medically necessary, Medicaid-covered services to eligible clients. Administrative procedures such as prior authorization, pre-certification, referrals, and claims/encounter data filing may differ from traditional Medicaid (fee-for-service) and from MCO to MCO. Providers should contact the client's specific MCO for details.

Effective for dates of service on or after November 1, 2020, prior authorization criteria for burosumab-twza (Crysvita) will be updated for Texas Medicaid.

The client age criteria for treatment of X-linked hypophosphatemia will change from one year of age or older to six months of age or older.

Burosumab-twza (Crysvita) will also be a benefit for treatment of fibroblast growth factor 23 (FGF23)-related hypophosphatemia in tumor-induced osteomalacia associated with phosphaturic mesenchymal tumors. For initial prior authorization approval, the following criteria must be met:

  • The client is two years of age or older.
  • The client has a diagnosis of FGF23-related hypophosphatemia produced by an underlying tumor that cannot be localized or is not amenable to surgical excision.
  • The prescriber discontinues any oral phosphate or vitamin D analog supplement at least two weeks prior to starting burosumab-twza (Crysvita) therapy.
  • The prescriber agrees to measure serum phosphate throughout therapy.

For more information, call the TMHP Contact Center at 800-925-9126.